OBJECTIVE: To dynamically analyze the effects of leosimendan combined with dopamine on renal function in patients with acute heart failure based on DID model. METHODS: A total of 225 patients with acute heart failure admitted to this hospital from Jan. 2019 to Jan. 2021 were divided into research group（112 cases） and control group（113 cases） via the random number table. The control group was given conventional therapy for cardiac failure combined with dopamine for intravenous pump [from 1 to 5 μg/（kg·min）]; while the research group was given leosimendan based on the control group

with the initial loading dosage（12 μg/kg） administrated intravenously for 10 min

followed by intravenous drip at the velocity of 0.1 μg/（kg·min） for cardiac tonic treatment. Indicators of renal function and cardiac function were compared between two groups before and after treatment

the clinical efficacy of levosimendan was evaluated by using the DID method

and the parallel trend test graphs were plotted by using the Coefplot package in Stata software. RESULTS: After 1

2

3 and 4 weeks of treatment

the left ventricular ejection fraction（LVEF）

stroke volume（SV）

cardiac index（CI） and glomerular filtration rate（GFR） of both groups were significantly higher than those before treatment

the blood urea nitrogen（BUN）

serum creatinine（SCr） and N-terminal B-type natriuretic peptidogen（NT-proBNP） levels of both groups were significantly lower than those before treatment; after 1

2 and 3 weeks of treatment

the LVEF

SV

CI and GFR levels of the research group were significantly higher than those of the control group

the BUN

SCr and NT-proBNP levels of research group were significantly lower than those of the control group

with statistically significant differences（P<0.05）; after 4 weeks of treatment

there were no significant difference in the above indexes between the two groups（P>0.05）. The results of DID effect analysis showed that there was a statistically significant improvement in cardiac and renal function between the treatment regimen and the AHF patients（P<0.05）. CONCLUSIONS: Levosimendan combined with dobutamine can improve early renal function

increase cardiac function and left ventricular activity in patients with acute heart failure.